Wound Center Biologics Inventory: Par Levels, Expiry and Wastage Control
Biologic allografts are expensive, single-use, and date-limited. That combination makes inventory the most reliably underestimated cost center in a wound center's biologics program. The clinical case for the product is argued once, at the value analysis committee. The inventory design is what determines whether the program's cost per application matches the number that was approved, and it is usually designed by nobody in particular.
The two failure modes are symmetrical and both are common. Stock too little and the correct size is unavailable when a case is scheduled, which either delays the application or pushes the clinician to open a larger graft than the wound needs. Stock too much and product expires on the shelf. Both show up as wastage, one as the cost of an oversized opening and the other as the cost of a discarded unit, and neither appears in a per-unit purchase price comparison.
This guide covers the operational controls: how to derive par levels from measured consumption rather than from storage space, how to keep expiry from becoming the dominant waste category, how to reconcile inventory in a way that surfaces the real problems, and what documentation a surveyor or auditor will expect to see. Product choice and clinical application are separate topics; the comparison and evidence material is covered elsewhere on this site.
Why biologics inventory behaves differently from consumables
Four properties separate allografts from the gauze and saline on the same shelf, and each one changes a control.
Unit cost. A single graft can cost more than a month of routine consumables. That shifts the tolerance for error: a stockout of gauze is an inconvenience, a stockout of the correct graft size is a scheduling problem, and an expired graft is a write-off that has to be explained. Dating. Every unit carries a processor-set expiration date, and the usable window is shorter than most consumables. This makes first-expiry-first-out mandatory rather than advisory, and it makes the date a planning input rather than a label detail. Single use. There is no partial use and no return to stock once a package is opened. Every sizing decision is a consumption decision, which means the size mix held on the shelf directly determines how much product is opened and not applied. Lot-level traceability. Allografts are tracked by lot, and in the United States the tissue-tracking requirements under 21 CFR Part 1271 Subpart D include records that allow a product to be traced from the processor to the recipient. That makes the inventory record a regulatory document, not just an operational convenience. A quantity-only stock count does not satisfy it.Deriving par levels from measured consumption
A par level is a reorder trigger, not a storage target. The number should be the point at which a reorder is placed so that stock arrives before usage depletes what is on the shelf. Three inputs determine it.
Measured usage, per SKU, per month. Not the year-one projection from the launch business case. Pull actual consumption by product and by size from the application record for the last three to six months. Wound size distribution in a real practice is usually narrower than the catalog assumes, and the measured distribution is what should drive the size mix. Supplier lead time, converted to months. If the processor ships in two weeks, the lead time is roughly half a month, and the par level needs to cover usage over that window plus a buffer. Lead time is a contractual and logistical fact that should be confirmed rather than assumed, and it should be re-confirmed when a supplier changes. Variability, expressed as a buffer. Usage that is steady needs a thin buffer. Usage that swings with referral patterns, seasonal case mix, or a small number of high-acuity patients needs a thicker one. For low-volume SKUs, the honest conclusion is often that a formal par level does not make sense at all and the item should be ordered per case.Two adjustments override the arithmetic. Short-dated and high-cost products should carry thinner par levels than consumption alone suggests, because the cost of an expired unit exceeds the cost of a short stockout for those items. And any product where a stockout would force a clinically inferior substitute deserves a thicker buffer regardless of cost, because the comparison is not stockout versus holding cost, it is substitute application versus correct application.
Set the par level once, review it quarterly against measured consumption, and treat a persistent stockout or a persistent expiry event as evidence that the number is wrong rather than as bad luck.
Controlling expiry before it becomes wastage
Expiry is the largest wastage category in most biologics programs, and most of it is preventable with shelf discipline rather than with forecasting sophistication.
First-expiry-first-out, physically enforced. Rotation works when the shelf is organized by expiry date and when the earliest-dated units are at the front. A shelf organized by arrival order is the structural cause of most expiry waste, and it is fixed in an afternoon. Date visibility at the point of selection. The person choosing a graft for a case should be able to see the expiration date without lifting the package out of a bin. Front-facing dates, a bin that holds one lot at a time, or a small label on the bin edge all work. Monthly expiry report, acted on. A report listing everything expiring in the next 60 and 90 days, reviewed against scheduled cases and against the consumption rate for that SKU. The output of the review should be a decision: use it, transfer it to a site that will use it, or accept the write-off knowingly. An expiry report that is generated and not acted on is worse than no report, because it creates a record that the problem was visible. A defined disposition for expired units. Quarantine them off the working shelf, document the removal, and follow institutional policy and the processor's instructions for the disposition. Leaving an expired unit in place "to be dealt with later" is how it gets applied. Sizing discipline as a wastage control. A clinician who opens the only available size for a wound that needed a smaller one consumes the difference. Keeping the common small and mid sizes reliably in stock prevents a meaningful share of wastage, and it is a stronger lever than coaching on application technique.Storage, monitoring and capacity
Storage requirements are product-specific and are set by the processor, so the inventory plan has to be built around whichever categories the center stocks. Ambient, refrigerated, and frozen storage each carry their own capacity, their own monitoring, and their own excursion procedure.
Three planning points are worth making explicitly. First, capacity should be sized against the par level plus a receiving buffer, not against the par level alone, because orders arrive in full and need somewhere to sit. Second, temperature monitoring needs to cover the storage location continuously, and the excursion procedure needs to be written before the first excursion rather than during it. Third, the receiving step is where identity, condition, and transit history are established, and it is a separate control from inventory management. The checks for that step are covered in the graft handling and storage material on this site.
Reconciliation that surfaces real problems
A monthly physical count against the inventory system is the baseline. Whether that count is useful depends entirely on whether it is done by lot.
A quantity-only reconciliation answers "do we have as many units as the system says." A lot-level reconciliation answers "do we have the lots the system says, and are any lots missing, expired, or unaccounted for." Only the second detects a unit that was consumed without documentation, which is the failure that matters for traceability and the one that a surveyor will find. Where lot tracking is in place, reconcile at lot level.
Cycle counting the highest-cost and shortest-dated items more frequently than monthly is a reasonable refinement, because those are where a discrepancy costs the most and where a missing unit is most likely to be an expiry event recorded late.
Discrepancy investigation should be routine rather than exceptional. A unit that cannot be accounted for is a documentation problem until proven otherwise, and the investigation should look first at applications where the lot was not recorded at the point of use, because that is the most common cause.
The documentation a surveyor will expect
The inventory system, the receiving records, the application records, and the temperature logs are separate documents that have to agree with each other. Audits do not check whether each document is internally tidy; they check whether they reconcile.
- Receiving records tying each shipment to a purchase order, a lot number, and a lot-specific certificate of analysis. - Storage temperature logs covering the full period the product was on site, with an excursion procedure and records of any excursions. - Application records linking each applied unit to a patient, a date, a lot, and a product. - Disposition records for expired, damaged, or returned units. - Reconciliation records showing counts against system quantities, by lot where applicable.
The most common finding in this set is a gap between the application record and the inventory decrement, where a graft was applied and documented clinically but the inventory was adjusted at month end from memory. That gap is where traceability breaks.
What the inventory design actually buys
The point of all of this is not compliance for its own sake. A wound center that derives par levels from measured consumption, enforces first-expiry-first-out, reconciles by lot, and acts on a monthly expiry report typically sees two things: the cost per application converges on the number the value analysis committee approved, and the sizing decisions stop being driven by what happened to be in stock.
That is the difference between a biologics program that is evaluated once and a program that holds up under review. The clinical evidence and the product comparison decide whether a graft belongs in the practice. The inventory design decides whether it works there.
This content is informational and not medical advice; it is not a substitute for professional diagnosis or treatment. Reimbursement, coverage, and accreditation requirements change; verify current coding and coverage with the appropriate payer and surveyor organization, and follow the manufacturer's Instructions for Use for all product handling questions.References
1. FDA. Current Good Tissue Practice for Human Cell, Tissue, and Cellular and Tissue-Based Product Establishments; 21 CFR Part 1271 Subpart D (storage, 1271.260; records, 1271.265; tracking, 1271.290). 2. American Association of Tissue Banks. Standards for Tissue Banking (handling, storage, and chain-of-custody requirements). 3. Centers for Medicare & Medicaid Services. Medicare Benefit Policy Manual, Chapter 15 (coverage of surgical dressings and skin substitutes). 4. Snyder D, Sullivan N, Margolis D, et al. Skin Substitutes for Treating Chronic Wounds. Agency for Healthcare Research and Quality (AHRQ) Technology Assessment. 2020. 5. Serena TE, et al. Dehydrated human amnion/chorion membrane treatment of venous leg ulcers: correlation between 4-week and 24-week outcomes. J Wound Care. 2015. PMID: 26551645. 6. Tettelbach WH, et al. Dehydrated human amnion/chorion membrane to treat venous leg ulcers: a cost-effectiveness analysis. J Wound Care. 2024. PMID: 38457290.